Research programme: atherosclerosis therapy - UCB

Drug Profile

Research programme: atherosclerosis therapy - UCB

Alternative Names: NBI-74330

Latest Information Update: 27 Nov 2007

Price : $50

At a glance

  • Originator UCB
  • Class Acetamides; Pyrimidines
  • Mechanism of Action CXCR3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Atherosclerosis

Most Recent Events

  • 07 Nov 2007 Pharmacodynamics data from a preclinical study in Atherosclerosis presented at the 80th Scientific Sessions of the American Heart Association (AHA-2007)
  • 05 Jan 2005 Celltech Group has been acquired by UCB
  • 08 Dec 2003 The integration of Oxford GlycoSciences into Celltech Group has been completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top